Código QR (código de barras bidimensional)

Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis

Abstract Background Hepatocellular carcinoma (HCC) is a common primary malignant tumor which usually progresses to an advanced stage because of late diagnosis. Sorafenib (Sora) is a first line medicine for advanced stage HCC; however, it has been faced with enormous resistance. Simvastatin (Sim) is...

ver descrição completa

Na minha lista:
Principais autores: Jiao Feng, Weiqi Dai, Yuqing Mao, Liwei Wu, Jingjing Li, Kan Chen, Qiang Yu, Rui Kong, Sainan Li, Jie Zhang, Jie Ji, Jianye Wu, Wenhui Mo, Xuanfu Xu, Chuanyong Guo
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2020-01-01
coleção:Journal of Experimental & Clinical Cancer Research
Assuntos:
Sorafenib resistance
Simvastatin
Glycolysis
Hepatocellular carcinoma
PKM2
HIF-1α
Acesso em linha:https://doi.org/10.1186/s13046-020-1528-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados